Complications, adverse reactions, and insights with the use of botulinum toxin

Dermatologic Surgery

Volumn 29, Issue 5, 2003, Pages 549-556

  Klein, Arnold William ^a,b   Carruthers, Alastair ^b   Carruthers, Jean ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANESTHETIC AGENT; APRACLONIDINE; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; EMLA; METOCLOPRAMIDE; PENICILLAMINE; PHENYLEPHRINE; QUININE;

BLEPHAROSPASM; DIPLOPIA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ECCHYMOSIS; ECTROPION; EDEMA; ERYTHEMA; FACE MALFORMATION; FACE MUSCLE; FATIGUE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERHIDROSIS; HYPESTHESIA; IMMOBILIZATION; MALAISE; MUSCLE CONTRACTILITY; MUSCLE WEAKNESS; MYASTHENIA; NAUSEA; PAIN; PARALYSIS; PRIORITY JOURNAL; PTOSIS; RASH; REVIEW; SKIN BRUISING; URTICARIA;

BOTULINUM TOXINS; HUMANS; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; PARALYSIS;

EID: 0037610914     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4725.2003.29129.x     Document Type: Review

References (52)

1. Lamanns C. The most poisonous poison. Science 1969;130:763-72.
2. Dertzbaugh MT, West MW. Mapping of protective and crossreactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine 1996;16:1538-44.
3. Somers E, DasGupta BR. Clostridium botulinum type A, B, C1 and E produce proteins with or without hemagglutinating activity: do they share common amino acid sequences and genes? J Protein Chem 1991;10:415-25.
4. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther 1983;19:165-94.
5. Bonventre PF, Kempe LL. Physiology of toxin production by Clostridium botulinum types A and B: III: effect of pH and temperature during incubation on growth, autolysis, and toxin production. Appl Microbiol 1959;7:374-7.
6. Townsend CT, Yee L, Mercer WA Inhibition of the growth of Clostridium botulinum by acidification. Food Res 1954;19:1-7.
7. Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A therapy for hyperkinetic facial lines: results of a double-blind, placebo controlled study. Plast Reconstr Surg 1994;94:94-9.
8. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980;212:16-2.
9. Personal communication, Roger Aoki, Allergan, 2002.
10. Hambleton P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol 1992;239:16-20.
11. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning biphasic switch of synaptic activity between sprouts and their patient terminals. PNAS. 1999;96:3200-5.
12. Baffi RA, Garnick RL. Quality control issues in the analysis of lyophilized proteins. Dev Biol Standard 1991;74:181-4.
13. Aoki RJ. Botulinum toxin and possible central effects. Neurology 2001;248(Suppl 1):1/3-1/10.
14. Borodic GE. Ferranter: Orbicularis Muscle Histology After Repetitive Injections of Botulinum A Toxin. Atlanta, GA: Presented in annual meeting of American Academy of Ophthalmology, 1990.
15. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1999;49:189-94.
16. Blitzer A, Binder WJ, Aviv JE, et al. The management of hyperfunctional facial lines with botulinum toxin: a collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 1997;123:389-92.
17. Klein A. Cosmetic therapy with botulinum toxin: anecdotal memoirs. Dermatol Surg 1996;22:757-9.
18. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981;33:155-88.
19. Lange DH, Brin MF, Warner CL, et al. Distal effects of locally injected botulinum toxin: incidences and effects. Adv Neurol 1988;50:609.
20. Blitzer A, Brin MF, Keen MS, Avis JE, et al. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993;119:1018-22.
21. Carruthers JDA, Carruthers JA. Treatment of glabellar frown lines with C botulinum-A exotoxin. J Dermatol Surg Oncol 1992;18: 17-21.
22. Garcia A, Fulton E. Cosmetic denervation of the muscles of facial expression with botulinum toxin. Dermatol Surg 1996;22: 39-43.
23. Hambleton P, Moore AP. Botulinum neurotoxins. Origin, structure, molecular actions, and antibody. In: Moore P, ed. Handbook of Botulinum Toxin Treatment. Oxford: Blackwell Science, 1995:16-27.
24. Guyuron B, Huddleston S. Aesthetic indications for botulinum toxin. Plast Reconstr Surg 1994;93:913-8.
25. Carruthers A, Carruthers J. Cosmetic uses of botulinum A exotoxin. Adv Dermatol 1997;12:325-47.
26. Alam M, Arndt KA, Dover JS. Severe, intractable headache after injection with botulinum. J Am Acad Dermatol 2002;46:62-5.
27. Report of the Therapeutics in Technology Assessment Subcommittee of the American Academy of Neurology: assessment: the clinical usefulness of botulinum toxin A in treating neurologic disorders. Neurology 1990;40:1132-335.
28. Visra VP. The changed image of botulinum toxin. BMJ 2002;325:1188.
29. Fraenkel AS, Kamer FM. Chemical brow lift. Arch Otolaryngol Head Neck Surg 1998;124:321-3.
30. Burns RL. Complications of Botulinum Exotoxin. Portland, OR: 25th Annual Clinical and Scientific Meeting of the ASDS, May 1998.
31. Britt MT, Burnstine MA. Iopidine allergy causing lower eyelid ectropion progressing to cicatricial entropion. Br J Ophthalmol 1999;83:992-3.
32. Brandt FS, Bellman B. Cosmetic use of botulinum A exotoxin for the aging neck. Dermatol Surg 1998;24:1232-4.
33. Sposito M. New indications for botulinum toxin type a in cosmetics: mouth and neck. Plast Reconstr Surg 2002;110:601-11.
34. Jankovic J, Brin MF Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-93.
35. Carruthers A, Carruthers JDA. The use of botulinum toxin to treat glabellar frown lines and other facial wrinkles. Cosmet Dermatol 1994;7:11-5.
36. Bushara KO, Jones JW, Park D, et al. Botulinum toxin and sweating [abstract]. Mov Disord 1995;10:391.
37. Mahant N, Clouston PD, Lorentz IT. The current use of botulinum toxin. J Clin Neurosci 2000;7:389-94.
38. Lange DI, Brin MF, Warner CL, et al. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987;10:552-5.
39. Olney RK, Aminoff MJ, Gelb DJ, et al. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988;38:1780-3.
40. Bhatia KP, Münchau A, Thompson PD, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 1999;67:90-3.
41. Tugnoli Y, Eleopra R, Quatrale R, et al. Botulism-like syndrome after BTX-A for local hyperhidrosis. Br J Dermatol 2002;147:8080.
42. Wilson F. Botulinum toxin-A risks overcome by proper technique. Cosmetic Surg Times 2001; March: 12.
43. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-6.
44. Gonnering RS. Negative antibody response to long-term treatment of facial spasm with botulinum toxin. Am J Ophthalmol 1988;105:313-5.
45. Mezaki T, Kaji R, Kohara N, et al. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 1995;45:506-8.
46. Ludlow CL, Hallett M, Rhew K, et al. Therapeutic use of type F botulinum toxin [letter]. N Engl J Med 1992;326:349-50.
47. Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 1998;13:150-4.
48. Göschel H, Wohlfaqrth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies: therapeutic consequences. Exp Neurol 1997;147:96-102.
49. National Institutes of Health. Clinical Use of Botulinum Toxin. National Institutes of Health Consensus Development Conference, 1990;8:1-20.
50. Borodic G, Johnson E, Goodnough M, et al.. Botulinum toxin therapy, immunologic resistance and problems with available materials. Neurology 1996;46:26-9.
51. Botox product monograph. Botox (Botulinum toxin type A) purified neurotoxin complex: advanced toxin technology. Irvine, CA: Allergan Inc., 1998:9161.
52. Personal communication from Alastair Carruthers, MD, May, 1999.